Investment Rating - The report maintains a "Buy" rating for the company, expecting the stock price to outperform the industry index by over 15% in the next six months [15]. Core Views - The company is expected to benefit from the increasing demand for energy-efficient temperature control in data centers, which will support its long-term growth [2][5]. - The company has experienced short-term performance pressure but is actively expanding its product offerings and market reach [2][6]. Financial Summary - Revenue for 2023 is projected at 635 million yuan, a year-on-year increase of 1.7%, while net profit is expected to be 35 million yuan, down 3.1% year-on-year [2]. - The company's gross margin for 2023 is 25.41%, a decrease of 1.24 percentage points year-on-year, primarily due to a shift in product mix towards lower-margin integrated products [1]. - The company anticipates net profits of 69 million yuan, 84 million yuan, and 102 million yuan for 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 64.9, 53.0, and 43.7 [6][9]. Business Development - The company is set to complete the "Nanjing Kaide Youyun Data Center Project" by March 31, 2024, which will serve as a demonstration project for energy-efficient data centers [3]. - The company has seen a 19.47% increase in revenue from integrated environmental products, which accounted for 42.10% of total revenue in 2023 [17]. - The company is enhancing its R&D capabilities, focusing on energy-saving control technologies, and has 43 core technologies and 22 ongoing projects [20].

华阳集团（002906.SZ） | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------|-------|-------|-------|--------|--------|------------------------------------------|-----------| | 财务指标 | 2022A | 2023A | 2024E | 2025E | 2026E | 增持（维持评级） | | | | | | | | | | | | | | | | | | | | | 营业收入（百万元） | 5,638 | 7,137 | 9,346 | 12,280 | 15,611 | 股票信息 | | | 增长率 yoy （ % ） | 25.6 | 26.6 | 31.0 | 31.4 | 27.1 | | | | 归母净利润（百万元） | 380 | 465 | 678 | 943 | 1,257 | 行业 | 汽车 | | 增长率 yoy （ % ） | 27.4 | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% relative to the industry index in the next six months [9]. Core Insights - The company has shown strong performance, exceeding market expectations with a revenue of 2.323 billion yuan in 2023, representing a year-on-year growth of 43.0%. The net profit attributable to shareholders reached 253 million yuan, a 39.6% increase compared to the previous year [1][2]. - The expansion of offline medical institutions continues, with the company adding 9 new outpatient chain stores in 2023, including 7 from acquisitions and 2 from self-construction, enhancing its presence in the East and Central China regions [2]. - The company has significantly increased its physician resources, with a total of 37,224 doctors, a 26.5% increase year-on-year. The number of self-owned doctors has also risen to 542, contributing 34.6% of the total revenue, which is a notable increase [2][4]. Financial Summary - Revenue is projected to grow from 3.056 billion yuan in 2024 to 5.189 billion yuan in 2026, with adjusted net profits expected to rise from 400 million yuan to 713 million yuan in the same period [1][4]. - The company's earnings per share (EPS) is forecasted to increase from 1.38 yuan in 2024 to 2.77 yuan in 2026, reflecting a strong growth trajectory [1][4]. - The price-to-earnings (P/E) ratio is expected to decrease from 31.7 in 2024 to 15.7 in 2026, indicating improving valuation metrics as earnings grow [1][4].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% relative to the industry index in the next six months [8][10]. Core Views - The company has shown resilience with a slight revenue increase in 2023, achieving a total revenue of 89.92 billion yuan, a year-on-year growth of 1.32%. However, the net profit decreased by 11.58% to 5.16 billion yuan [22][15]. - The company is focusing on strengthening its core business segments, particularly in tools, home appliances, and new energy, while also expanding into innovative areas such as robotics [3][25]. - The gross margin improved to 22.31%, up by 2.17 percentage points, driven by continuous innovation and cost reduction efforts [31]. Financial Summary - Revenue (in million yuan): - 2022A: 8,875 - 2023A: 8,992 - 2024E: 10,746 - 2025E: 12,906 - 2026E: 15,577 - Year-on-year growth rates: 14.3% (2022), 1.3% (2023), 19.5% (2024E) [2][10]. - Net Profit (in million yuan): - 2022A: 583 - 2023A: 516 - 2024E: 647 - 2025E: 851 - 2026E: 1,125 - Year-on-year growth rates: 3.2% (2022), -11.6% (2023), 25.5% (2024E) [2][10]. - ROE (%): - 2022A: 10.0 - 2023A: 8.0 - 2024E: 9.4 - 2025E: 11.1 - 2026E: 12.8 [2][10]. - EPS (latest diluted, in yuan): - 2022A: 0.46 - 2023A: 0.41 - 2024E: 0.51 - 2025E: 0.67 - 2026E: 0.89 [2][10]. Business Segment Performance - The tools segment achieved revenue of 32.41 billion yuan, with a year-on-year growth of 0.05%. The home appliances segment reached 31.66 billion yuan, growing by 2.41%. The new energy segment reported 21.40 billion yuan, up by 5.13% [3][25]. - The company is leveraging its leading position in the tools sector and expanding its market share overseas, while the home appliances segment benefits from technological upgrades [3][25].

证券研究报告 | 行业周报 2024 年 03月 30日 非银行金融 券商并购波澜再起，关注 KIMI 对金融 AI 的催化效应-非银周观点 本周市场受外部事件、汇率波动及密集财报披露等因素，叠加北向资金波动 强于大市（维持评级） 影响，市场振幅加大。目前披露的近 67%券商业绩正增长，KIMI 效应下， 金融 AI关注度提升，谨慎看好优质券商、金融 IT 及关注部分高分红非银金 行业走势 融个股机会。历史上，4 月走势更聚焦业绩，更多要回归基本面定价。本周 市场回暖，券商股滞涨，仍有潜在的修复动力。交易节奏层面而言，一方面， 非银行金融 沪深300 19% 需注意 KIMI受欢迎效应，以及界面财联社入局AI 国内首个千亿参数多模态 13% 金融大模型面市对金融AI板块催化的影响，包括同花顺、东方财富、财富趋 7% 2% 势有望获得资金青睐；另一方面，需注意对并购重组预期对板块的影响，重 -4% 点关注以浙商证券、国联证券、中国银河等为代表个股。 -10% -16% 保险股估值继续承压，关注寿险改革及基本面修复情况。本周十年期国债收 -22% 2023-03 2023-07 2023-11 2024-03 益 ...

证券研究报告 | 行业周报 2024 年 03月 28日 电力及公用事业 全国用电量增长 11%，局部地区水情形势严峻 股票 股票 投资 EPS （元） PE 强于大市（维持评级） 代码 名称 评级 2023E 2024E 2023E 2024E 002015.SZ 协鑫能科 增持 0.85 1.08 12.39 9.75 行业走势 600163.SH 中闽能源 增持 0.44 0.46 9.61 9.2 600674.SH 川投能源 增持 1.01 1.12 16.44 14.82 电力及公用事业 沪深300 600886.SH 国投电力 增持 0.84 0.99 17.71 15.03 9% 600900.SH 长江电力 买入 1.27 1.35 19.57 18.41 5% 600995.SH 南网储能 增持 0.43 0.5 21.81 18.76 1% -4% 资料来源：公司财报，长城证券产业金融研究院 -8% -12% 行业观点：全国用电量增长11%，局部地区水情形势严峻 -16% -21% 2024年 1-2月，全社会用电量累计 15316亿千瓦时，同比增长 11.0%， 2023-03 202 ...

Investment Rating - The report maintains a "Buy" rating for Jiangzhong Pharmaceutical, expecting a price increase of over 15% relative to the industry index in the next six months [20]. Core Insights - Jiangzhong Pharmaceutical achieved a revenue of 4.39 billion yuan in 2023, representing a year-on-year growth of 13%, and a net profit attributable to shareholders of 708 million yuan, up 18.4% year-on-year [10]. - The company continues to focus on high dividend payouts, with a proposed cash dividend of 0.70 yuan per share, accounting for 62.20% of the net profit attributable to shareholders [10][13]. - The company is expected to achieve revenues of 5.00 billion yuan, 5.62 billion yuan, and 6.41 billion yuan in 2024, 2025, and 2026, respectively, with corresponding net profits of 802 million yuan, 927 million yuan, and 1.08 billion yuan [7][22]. Business Segments Summary - The OTC segment generated revenues of 3.05 billion yuan, with a year-on-year growth of 16.52%, accounting for 69.48% of total revenue [2]. - The health segment, focusing on high-end nourishment and recovery nutrition, saw a revenue increase of 58.77%, indicating strong growth potential [3]. - The prescription drug segment experienced a revenue decline of 10.86%, primarily due to the impact of national drug procurement policies [24]. Financial Performance - The overall gross margin for the company improved to 65.31%, with the OTC segment gross margin at 71.70%, while the prescription drug segment saw a decline to 63.21% [26]. - The company’s operating income for 2023 was 4.39 billion yuan, with a projected growth rate of 13.9% for 2024 [22]. - The return on equity (ROE) is expected to rise from 17.1% in 2023 to 18.8% by 2026 [22]. Dividend Policy - Jiangzhong Pharmaceutical has maintained a high dividend payout ratio, with historical rates of 108.33% and 121.02% in 2021 and 2022, respectively, highlighting its commitment to returning value to shareholders [13].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of 5% to 15% relative to the industry index over the next six months [12]. Core Insights - The company achieved a revenue of 58.147 billion yuan in 2023, representing a year-on-year growth of 15.83%, while the net profit attributable to shareholders decreased by 45.00% to 2.024 billion yuan [1][2]. - The gross margin for 2023 was 14.11%, down by 3.76 percentage points, but the company effectively controlled expenses, with a total expense ratio of 13.54%, a decrease of 2.73 percentage points [2]. - The jewelry fashion segment, the core business of the company, generated revenue of 36.727 billion yuan, an increase of 11.05% year-on-year, despite a slight decline in gross margin [3]. Financial Performance Summary - Revenue (in million yuan): - 2022: 50,200 - 2023: 58,147 - 2024E: 64,630 - 2025E: 70,362 - 2026E: 75,453 - Year-on-year growth rates for revenue: - 2022: -3.4% - 2023: 15.8% - 2024E: 11.1% - 2025E: 8.9% - 2026E: 7.2% [1][8]. - Net profit (in million yuan): - 2022: 3,680 - 2023: 2,024 - 2024E: 2,410 - 2025E: 2,792 - 2026E: 3,208 - Year-on-year growth rates for net profit: - 2022: -2.4% - 2023: -45.0% - 2024E: 19.1% - 2025E: 15.8% - 2026E: 14.9% [1][8]. Business Segment Performance - The company’s various business segments showed strong performance in 2023: - Industrial operations: 41.694 billion yuan, +7.94% YoY - Commercial operations and property services: 2.895 billion yuan, +17.79% YoY - Property development and sales: 13.558 billion yuan, +48.72% YoY [3]. - The company expanded its jewelry fashion segment significantly, with a total of 4,994 retail outlets by the end of 2023, adding 429 new outlets during the year [3].

公司动态点评 P.3 请仔细阅读本报告末页声明 本报告署名分析师在此声明：本人具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，在执业过程中恪守独立诚 信、勤勉尽职、谨慎客观、公平公正的原则，独立、客观地出具本报告。本报告反映了本人的研究观点，不曾因，不因，也将不会因本 报告中的具体推荐意见或观点而直接或间接接收到任何形式的报酬。 执业证书编号：S1070523110001 公司动态点评 长城证券股份有限公司（以下简称长城证券）具备中国证监会批准的证券投资咨询业务资格。 妙可蓝多（600882.SH） | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------|-------|-------|-------|-------|-------|------------------------------------------|----------| | 财务指标 | 2022A | 2023A | 2024E | 2025E | 2026E | 买入（首次评级） | | | 营业收入（百万元） | 4,830 ...

新集能源（601918.SH） 拥有华东区位优势，煤电一体化进程持续推进 事件：新集能源发布 2023 年年度报告：2023 年公司实现营业收入 128.45 亿元，同比增长 7.01%，归母净利润为 21.09 亿元，同比增长 1.57%， 扣非后的归母净利润为 20.53亿元，同比减少 1.47%。基本每股收益为 0.81 元，同比增长 1.50%，加权平均净资产收益率为 16.84%，同比减少 2.8pct。 点评： 发电业务方面火电成本控制得当，盈利改善。根据公司 2023 年报，1）产销 量：2023 年公司火电发电量为 103.93 亿千瓦时（同比-2.67%），火电上网 电量为 98.72 亿千瓦时（同比-2.78%）。2）售价：售电价为 409.79 元/兆瓦 时（同比+0.40%）。3）成本与盈利：单位售电成本为 317.16 元/兆瓦时 （-0.42%），单位售电毛利为 93.70 元/兆瓦时（同比+4.44%）。 请仔细阅读本报告末页声明 作者 邮箱：yiw@cgws.com 相关研究 公司费率同比减少，降本增效初有成效。根据公司 2023 年报，2023 年公司 销售费用率为 0.45 ...